AbbVie Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'AbbVie Inc. - Product Pipeline Review - 2016', provides an overview of the AbbVie Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by AbbVie Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of AbbVie Inc. - The report provides overview of AbbVie Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses AbbVie Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features AbbVie Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate AbbVie Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for AbbVie Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding AbbVie Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 AbbVie Inc. Snapshot 6 AbbVie Inc. Overview 6 Key Information 6 Key Facts 6 AbbVie Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 AbbVie Inc. - Pipeline Review 14 Pipeline Products by Stage of Development 14 Pipeline Products - Monotherapy 15 Pipeline Products - Combination Treatment Modalities 16 Pipeline Products - Partnered Products 17 Pipeline Products - Out-Licensed Products 20 AbbVie Inc. - Pipeline Products Glance 22 AbbVie Inc. - Late Stage Pipeline Products 22 AbbVie Inc. - Clinical Stage Pipeline Products 25 AbbVie Inc. - Early Stage Pipeline Products 27 AbbVie Inc. - Drug Profiles 30 adalimumab 30 daclizumab 33 elotuzumab 37 ibrutinib 39 venetoclax 46 Viekira-3QD 50 (ombitasvir + paritaprevir + ritonavir) + dasabuvir 51 atrasentan hydrochloride 52 elagolix sodium 54 fluvoxamine maleate 56 glecaprevir 57 glecaprevir + pibrentasvir 59 ombitasvir 61 paricalcitol 63 paritaprevir 64 pibrentasvir 66 upadacitinib tartrate 67 veliparib 68 depatuxizumab mafodotin 72 ABT-122 74 ABT-436 76 ABT-981 77 depatuxizumab 78 navitoclax dihydrochloride 79 ABBV-075 81 ABBV-084 82 ABBV-085 83 ABBV-221 84 ABBV-672 85 ABBV-838 86 ABBV-8E12 87 ABT-165 88 ABT-257 89 ABT-399 90 ABT-555 91 ABT-700 92 ABT-767 93 ABT-957 94 ilorasertib 95 A-1048400 97 A-1262543 98 A-1264087 99 A-431404 100 A-705253 101 A-889425 102 A-988315 103 ABT-207 104 ABT-737 105 APG-880 107 Biologics for Undisclosed Indication 108 h-5F9AM8 109 Monoclonal Antibodies to Inhibit RGMa for Multiple Sclerosis 110 Monoclonal Antibody Conjugates for Oncology 111 Small Molecule to Inhibit PKC Theta for Autoimmune Disease 112 Small Molecule to Inhibit WEE-1 for Oncology 113 Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology 114 SOL-1 115 A-893 116 Monoclonal Antibodies for Chronic Pain 117 Small Molecules to Inhibit CDPK1 for Protozoal Infections 118 Small Molecules to Inhibit Jak1 for Undisclosed Indication 119 Small Molecules to Inhibit MCL-1 for Cancer 120 AbbVie Inc. - Pipeline Analysis 121 AbbVie Inc. - Pipeline Products by Target 121 AbbVie Inc. - Pipeline Products by Route of Administration 125 AbbVie Inc. - Pipeline Products by Molecule Type 126 AbbVie Inc. - Pipeline Products by Mechanism of Action 127 AbbVie Inc. - Recent Pipeline Updates 130 AbbVie Inc. - Dormant Projects 177 AbbVie Inc. - Discontinued Pipeline Products 182 Discontinued Pipeline Product Profiles 182 AbbVie Inc. - Company Statement 187 AbbVie Inc. - Locations And Subsidiaries 190 Head Office 190 Other Locations & Subsidiaries 190 Appendix 198 Methodology 198 Coverage 198 Secondary Research 198 Primary Research 198 Expert Panel Validation 198 Contact Us 198 Disclaimer 199
List of Tables
AbbVie Inc., Key Information 11 AbbVie Inc., Key Facts 11 AbbVie Inc. - Pipeline by Indication, 2016 13 AbbVie Inc. - Pipeline by Stage of Development, 2016 19 AbbVie Inc. - Monotherapy Products in Pipeline, 2016 20 AbbVie Inc. - Combination Treatment Modalities in Pipeline, 2016 21 AbbVie Inc. - Partnered Products in Pipeline, 2016 22 AbbVie Inc. - Partnered Products/ Combination Treatment Modalities, 2016 23 AbbVie Inc. - Out-Licensed Products in Pipeline, 2016 25 AbbVie Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 26 AbbVie Inc. - Pre-Registration, 2016 27 AbbVie Inc. - Filing rejected/Withdrawn, 2016 28 AbbVie Inc. - Phase III, 2016 29 AbbVie Inc. - Phase II, 2016 30 AbbVie Inc. - Phase I, 2016 31 AbbVie Inc. - Preclinical, 2016 32 AbbVie Inc. - Discovery, 2016 34 AbbVie Inc. - Pipeline by Target, 2016 126 AbbVie Inc. - Pipeline by Route of Administration, 2016 130 AbbVie Inc. - Pipeline by Molecule Type, 2016 131 AbbVie Inc. - Pipeline Products by Mechanism of Action, 2016 132 AbbVie Inc. - Recent Pipeline Updates, 2016 135 AbbVie Inc. - Dormant Developmental Projects,2016 182 AbbVie Inc. - Discontinued Pipeline Products, 2016 187 AbbVie Inc., Subsidiaries 195
List of Figures
AbbVie Inc. - Pipeline by Top 10 Indication, 2016 13 AbbVie Inc. - Pipeline by Stage of Development, 2016 19 AbbVie Inc. - Monotherapy Products in Pipeline, 2016 20 AbbVie Inc. - Partnered Products in Pipeline, 2016 22 AbbVie Inc. - Pipeline by Top 10 Target, 2016 126 AbbVie Inc. - Pipeline by Route of Administration, 2016 130 AbbVie Inc. - Pipeline by Molecule Type, 2016 131 AbbVie Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 132
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among otRead More...
Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to driveRead More...
Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance drivRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.